Neoadjuvant chemotherapy has proven clinical benefit in mMuscle- invasive bladder cancer. Cisplatin is the likely driver of this benefit. Textbook definitions of cisplatin ineligibility may restrict almost 50% of patients from therapy.
Neoadjuvant chemotherapy has proven clinical benefit in mMuscle- invasive bladder cancer. Cisplatin is the likely driver of this benefit. Textbook definitions of cisplatin ineligibility may restrict almost 50% of patients from therapy.